This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
RIVERA, VICTOR
| Item Type | Name |
|
Academic Article
|
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
|
|
Academic Article
|
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
|
|
Academic Article
|
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
|
|
Academic Article
|
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
|
|
Academic Article
|
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
|
|
Academic Article
|
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
|
|
Academic Article
|
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
|
|
Concept
|
Imidazoles
|
|
Academic Article
|
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
|
|
Academic Article
|
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
|
|
Academic Article
|
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
|
|
Academic Article
|
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
|
|
Academic Article
|
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
|
|
Academic Article
|
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
|